The synthesis and the study of the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides
Keywords:7H-[1, 2, 4]triazolo[3, 4-b][1, 3, 4]thiadiazine, anastrozole, antitumor activity
Aim. To synthesize and study the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine derivatives.
Results and discussion. To determine the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides, the in vitro study was conducted on 60 lines of cancer cells (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) according to the standard procedure of the mitotic activity assessment of new potential bioactive compounds by the fluorescent coloring method (sulforhodamine B as a dye). It was performed in the US National Сancer Institute within the Development Therapeutic Program. It has been found that derivatives of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine exhibit the antineoplastic activity against a wide range of cancer cells lines and are promising core structures for creating new effective anticancer agents.
Experimental part. 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides were synthesized by the interaction of 4-amino-5-R-4H-1,2,4-triazole-3-thiols with 4-methoxyphenacyl bromide in ethyl acetate. The 1Н NMR spectra were recorded on a Bruker VXR-300 spectrometer (Germany) with the working frequency of 299.945 MHz.
Conclusions. A series of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides has been synthesized. The anticancer activity of the compounds obtained has been studied in the National Cancer Institute on 60 lines of tumor cells. Compounds that exhibit high levels of the antitumor activity have been found. It has been shown that the replacement of 3-H in compound 3a with ethyl or pentyl radicals leads to increase in the antitumor activity against MDA-MB-468 breast cancer cells.
Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer (accessed Apr 10, 2020).
Plummer, M.; de Martel, C.; Vignat, J.; Ferlay, J.; Bray, F.; Franceschi, S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 2016, 4 (9), e609 – e616. https://doi.org/10.1016/S2214-109X(16)30143-7.
Ogasa, Y.; Kuwamura, T.; Akiyoshi, T.; Murakami, S.; Tanaka, H.; Umeda, S.; Suematsu F. Evaluation of patient adherence to anastrozole therapy for breast cancer. Gan To Kagaku Ryoho 2018, 45 (6), 965 – 968.
Barros-Oliveira, M. d. C.; Costa-Silva, D. R.; Andrade, D. B. d.; Borges, U. S.; Tavares, C. B.; Borges, R. S.; Silva, J. d. M.; Silva, B. B. d. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review. Revista da Associação Médica Brasileira 2017, 63, 371 – 378. http://dx.doi.org/10.1590/1806-9282.63.04.371.
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003, 98 (9), 1802 – 1810. https://doi.org/10.1002/cncr.11745.
Kravchenko, T. V.; Panasenko, O. I.; Knysh, E. G. Biological activity of the derivatives of 1,2,4-triazole. Farmatsevtychnyi zhurnal 2018, 5, 25 – 30. https://doi.org/10.32352/0367-3057.5.16.02.
The BIG 1-98 Collaborative Group. Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. N. Engl. J. Med. 2009, 361 (8), 766 – 776. https://doi.org/10.1056/NEJMoa0810818.
Aggarwal, N.; Kumar, R.; Dureja, P.; Khurana, J. M. Synthesis, antimicrobial evaluation and QSAR analysis of novel nalidixic acid based 1,2,4-triazole derivatives. Eur. J. Med. Chem. 2011, 46 (9), 4089 – 4099. https://doi.org/10.1016/j.ejmech.2011.06.009.
Kumar, D.; Narayanam, M. K.; Chang, K.-H.; Shah, K. Synthesis of Novel Indolyl-1,2,4-triazoles as Potent and Selective Anticancer Agents. Chemical Biology & Drug Design 2011, 77 (3), 182 – 188. https://doi.org/10.1111/j.1747-0285.2010.01051.x.
Khan, I.; Zaib, S.; Ibrar, A.; Rama, N. H.; Simpson, J.; Iqbal, J. Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines. Eur. J. Med. Chem. 2014, 78, 167 – 177. https://doi.org/10.1016/j.ejmech.2014.03.046.
Purohit, D. H.; Dodiya, B. L.; Ghetiya, R. M.; Vekariya, P. B.; Joshi H. S. Synthesis and antimicrobial activity of some new 1,3,4-thiadiazoles and 1,3,4-thiadiazines containing 1,2,4-triazolo nucleus. Acta Chim. Slov. 2011, 58, 53 – 59.
Prakash, O.; Aneja, D. K.; Hussain, K.; Lohan, P.; Ranjan, P.; Arora, S.; Sharma, C.; Aneja, K. R. Synthesis and biological evaluation of dihydroindeno and indeno[1,2-e][1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as antimicrobial agents. Eur. J. Med. Chem. 2011, 46 (10), 5065 – 5073. https://doi.
El Shehry, M. F.; Abu-Hashem, A. A.; El-Telbani, E. M. Synthesis of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents. Eur. J. Med. Chem. 2010, 45 (5), 1906 – 1911. https://doi.org/10.1016/j.ejmech.2010.01.030.
Teicher, B. A.; Andrews, P. A., Eds. Anticancer Drug Development Guide; Humana Press: 2004.
Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Res. 1988, 48 (3), 589 – 601.
Carter, P. H.; Scherle, P. A.; Muckelbauer, J. A.; Voss, M. E.; Liu, R.-Q.; Thompson, L. A.; Tebben, A. J.; Solomon, K. A.; Lo, Y. C.; Li, Z.; Strzemienski, P.; Yang, G.; Falahatpisheh, N.; Xu, M.; Wu, Z.; Farrow, N. A.; Ramnarayan, K.; Wang, J.; Rideout, D.; Yalamoori, V.; Domaille, P.; Underwood, D. J.; Trzaskos, J. M.; Friedman, S. M.; Newton, R. C.; Decicco, C. P. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (21), 11879 – 11884. https://doi.org/10.1073/pnas.211178398.
Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 1992, 19 (6), 622 – 638.
Hou, N.; Xu, L. J. Synthesis and bacteriostatic activity of new thiosemicarbazone derivatives – aminomercaptotriazole Schiff bases. Yaoxue Xuebao 1992, 27 (10), 738 – 742.
5-(β-hydroxyethylthio)-4-amino-1,2,4-(4H)-triazol. In Sintezy geterotsiklicheskikh soyedineniy; Mndzhoyan, A. L., Ed.; Academy of Sciences of Armenian SSR: Yerevan, 1964; Vol. 6, pp. 41 – 43.
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:
1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.
3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).